IEH Academy

Mastering FDA Compliance: Regulatory Forms, Warning Letters, and Consent Decrees

Course details

Self-Paced eLearning

199.00

2 Hours

Dr. Suf Alkhaldi

Carol Cave

This course provides a comprehensive understanding of FDA regulatory requirements, focusing on inspection protocols, compliance strategies, and managing forms such as 482 and 483.

Benefits and Learning Objectives

Attendees will learn practical approaches to responding to FDA observations, interpreting warning letters, and navigating consent decrees. Through expert insights and practical guidance, participants will be able to implement effective compliance measures and strengthen regulatory practices to maintain compliance and safeguard public health.

Agenda:

  • Identify regulatory requirements for FDA inspections.
  • Discuss strategies to prepare for FDA 482 and 483 inspections.
  • Explore expert insights on compliance with 482 and 483 forms.
  • Learn methods to interpret and respond to FDA warning letters.
  • Understand the implications of FDA warning letters on compliance.
  • Examine strategies for navigating FDA and company consent decrees.

Who Should Attend?

  • Regulatory Affairs Professionals
  • Quality Assurance Managers
  • Compliance Officers
  • FDA Inspection Teams
  • Manufacturing and Production Supervisors
  • Legal and Risk Management Experts
  • Clinical Research Coordinators
  • Consultants in Regulatory Compliance
  • Professionals involved in FDA-regulated product development

Registration and Payment

To register for this course, please visit our training portal.

Dr. Suf Alkhaldi

Meet the Instructors

Dr. Suf Alkhaldi

Dr. Suf Alkhaldi joined IEH as the Senior Vice President of Technical Services in 2023. He earned his M.S. and Ph.D. in Microbiology and Cell Molecular Biology from Oklahoma State University. He also conducted a postdoctoral study in Rumen Microbiology in Animal and Dairy Science at the University of Georgia and served as the manager of the DNA Microarray Lab at Yerkes National Primate Research Center at Emory University.

Before joining IEH, Dr. Alkhaldi spent over two decades at FDA which has been characterized by his exceptional contributions to innovation and regulatory excellence. He began as a researcher and food outbreak investigator at the Center for Food and Applied Nutrition (CFSAN), focusing on developing cutting-edge methods for identifying pathogenic bacteria in food using molecular techniques. With over 29 peer-reviewed manuscripts, 14 reviewed papers and book chapters, and co-editing “The Bad Bug Book,” he demonstrated a strong commitment to knowledge-sharing and food safety. Dr. Alkhaldi has played an instrumental role in resolving the FDA’s 2008 pepper outbreak investigation.

Throughout his extensive career at FDA, Dr. Alkhaldi held various roles, including Project Manager, Supervisor, and Senior Science Advisor in the Office of the Chief Scientist. He actively participated in influential working groups and the FDA Funded Centers of Excellence, reinforcing his dedication to advancing microbiology and FDA drug policies. Adding to his accomplishments, Dr. Alkhaldi received over 20 FDA awards between 2000 and 2023.

Dr. Alkhaldi was selected to lead the Office of Safety within the Office of Regulatory Affairs (ORA). His exceptional leadership during the COVID-19 pandemic was evident as he led a team of 24 Industrial Hygienists and safety professionals. Their dedication ensured the safety of 5,000 FDA employees and provided support for 16 FDA laboratories, demonstrating his significant impact in fostering a safe and innovative regulatory environment within the FDA and the broader field of food microbiology.

Carol Cave

Carol Cave

Ms. Carol Cave joined IEH as the Executive Vice President in 2024, bringing with her extensive expertise in regulatory affairs and consumer protection. She holds a B.S. in Consumer Economics from the University of Maryland.

Before joining IEH, Ms. Cave served as the Acting Associate Commissioner (ACRA) for the Office of Regulatory Affairs (ORA) at the Food and Drug Administration. In this role, she oversaw approximately 5000 ORA employees stationed across the U.S. and around the world.

Prior to her role as Acting ACRA, Ms. Cave served as Deputy Associate Commissioner, where she managed inspections, compliance, enforcement, field laboratory operations, import operations, and strategic planning.

Earlier in her career at the FDA, she served as the Assistant Commissioner of Import Operations, where she led the Office of Enforcement and Import Operations, ensuring FDA-regulated imported products comply with U.S. laws. Ms. Cave also led coordination efforts between the FDA and U.S. Customs and Border Protection, developing joint regulations, policies, procedures, and operations.

Before her tenure at the FDA, Ms. Cave was the Deputy Director of the Office of Compliance and Field Operations at the U.S. Consumer Product Safety Commission (CPSC). In this role, she collaborated with federal government agencies to identify potentially defective consumer products. With nearly 26 years at the CPSC, Ms. Cave held various leadership positions, including Director of State and Local Programs and Assistant Executive Director for the Office of Import Surveillance, ensuring the safety of consumer products nationwide.